TRINOVA - 2 is evaluating pegylated
liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.
The concept of
liposomal drug delivery has revolutionised the pharmaceutical field and came into praxis some 20 years ago when the first
liposomal formulation of the anti-cancer drug
doxorubicin was approved for clinical use.